2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu konsensus - konference, časopisecké články
Grantová podpora
ZIA ES101081-14
Intramural NIH HHS - United States
20417
Arthritis Research UK - United Kingdom
ZIA ES101081-13
Intramural NIH HHS - United States
ZID ES102465-05
Intramural NIH HHS - United States
MR/N003322/1
Medical Research Council - United Kingdom
ZIA ES101081-12
Intramural NIH HHS - United States
ZIA ES101081
Intramural NIH HHS - United States
20747
Arthritis Research UK - United Kingdom
ZID ES102465
Intramural NIH HHS - United States
ZIA ES101081-15
Intramural NIH HHS - United States
PubMed
28382778
PubMed Central
PMC5577002
DOI
10.1002/art.40060
Knihovny.cz E-zdroje
- MeSH
- alanintransaminasa metabolismus MeSH
- aldolasa metabolismus MeSH
- antirevmatika terapeutické užití MeSH
- aspartátaminotransferasy metabolismus MeSH
- cyklosporin terapeutické užití MeSH
- dermatomyozitida farmakoterapie metabolismus patofyziologie MeSH
- dítě MeSH
- glukokortikoidy terapeutické užití MeSH
- hodnocení výsledků péče pacientem MeSH
- hodnocení výsledků zdravotní péče MeSH
- kreatinkinasa metabolismus MeSH
- L-laktátdehydrogenasa metabolismus MeSH
- lidé MeSH
- logistické modely MeSH
- methotrexát terapeutické užití MeSH
- mladiství MeSH
- prednison terapeutické užití MeSH
- průzkumy a dotazníky MeSH
- reprodukovatelnost výsledků MeSH
- revmatologie MeSH
- rituximab terapeutické užití MeSH
- společnosti lékařské MeSH
- svalová síla MeSH
- výsledek terapie MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- Publikační typ
- časopisecké články MeSH
- konsensus - konference MeSH
- Geografické názvy
- Evropa MeSH
- Spojené státy americké MeSH
- Názvy látek
- alanintransaminasa MeSH
- aldolasa MeSH
- antirevmatika MeSH
- aspartátaminotransferasy MeSH
- cyklosporin MeSH
- glukokortikoidy MeSH
- kreatinkinasa MeSH
- L-laktátdehydrogenasa MeSH
- methotrexát MeSH
- prednison MeSH
- rituximab MeSH
OBJECTIVE: To develop response criteria for juvenile dermatomyositis (DM). METHODS: We analyzed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. They were further validated using data from the PRINTO trial of prednisone alone compared to prednisone with methotrexate or cyclosporine and the Rituximab in Myositis (RIM) trial. At a consensus conference, experts considered 14 top candidate criteria based on their performance characteristics and clinical face validity, using nominal group technique. RESULTS: Consensus was reached for a conjoint analysis-based continuous model with a total improvement score of 0-100, using absolute percent change in core set measures of minimal (≥30), moderate (≥45), and major (≥70) improvement. The same criteria were chosen for adult DM/polymyositis, with differing thresholds for improvement. The sensitivity and specificity were 89% and 91-98% for minimal improvement, 92-94% and 94-99% for moderate improvement, and 91-98% and 85-86% for major improvement, respectively, in juvenile DM patient cohorts using the IMACS and PRINTO core set measures. These criteria were validated in the PRINTO trial for differentiating between treatment arms for minimal and moderate improvement (P = 0.009-0.057) and in the RIM trial for significantly differentiating the physician's rating for improvement (P < 0.006). CONCLUSION: The response criteria for juvenile DM consisted of a conjoint analysis-based model using a continuous improvement score based on absolute percent change in core set measures, with thresholds for minimal, moderate, and major improvement.
Charles University Prague Czech Republic
Duke University Durham North Carolina
Emory University School of Medicine Atlanta Georgia
Great Ormond Street Hospital for Children NHS Trust London UK
Hannover Medical School Hannover Germany
Hospital de Niños Pedro de Elizalde University of Buenos Aires Buenos Aires Argentina
Hospital de Pediatría Garrahan Buenos Aires Argentina
Istituto Giannina Gaslini Pediatria 2 Reumatologia and Università degli Studi di Genova Genoa Italy
Istituto Giannina Gaslini Pediatria 2 Reumatologia PRINTO Genoa Italy
Istituto Giannina Gaslini Servizio di Epidemiologia e Biostatistica Genoa Italy
IWK Health Centre Halifax Nova Scotia Canada
Karolinska University Hospital Stockholm Sweden
Royal Hospital for Sick Children Glasgow UK and Royal Hospital for Sick Children Edinburgh UK
Semmelweis University Budapest Hungary
Social and Scientific Systems Inc Durham North Carolina
The Hospital for Sick Children Toronto Ontario Canada
Universidade Estadual Paulista Júlio de Mesquita Filho Botucatu Saõ Paulo Brazil
Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil
University Medical Centre Utrecht Wilhelmina Children's Hospital Utrecht The Netherlands
University of Firenze Florence Italy
University of Kansas City Medical Center Kansas City Kansas
Zobrazit více v PubMed
Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI) Arthritis Care Res (Hoboken) 2011;63(Suppl 11):S118–S157. PubMed PMC
Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001;40(11):1262–73. PubMed
Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, et al. Defining Clinical Improvement in Adult and Juvenile Myositis. J Rheumatol. 2003;30(3):603–17. PubMed
Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM, et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) 2003;42(12):1452–9. PubMed
Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G, et al. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum. 2008;59(1):4–13. PubMed
Ruperto N, Martini A. Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO) Arch Dis Child. 2011;96(6):596–601. PubMed
Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 2004;50(7):2281–90. PubMed
Ruperto N, Pistorio A, Ravelli A, Rider LG, Pilkington C, Oliveira S, et al. The Pediatric Rheumatology International Trials Organization provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2010;62:1533–41. PubMed PMC
Hasija R, Pistorio A, Ravelli A, Demirkaya E, Khubchandani R, Guseinova D, et al. Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study. Arthritis Rheum. 2011;63(10):3142–52. PubMed
Ruperto N, Pistorio A, Ravelli A, Hasija R, Guseinova D, Filocamo G, et al. Criteria to define response to therapy in paediatric rheumatic diseases. Eur J Clin Pharmacol. 2011;67(Suppl 1):125–31. PubMed
Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387(10019):671–8. PubMed
Felson DT, Furst DE, Boers M. Rationale and strategies for reevaluating the ACR20. J Rheumatol. 2007;34(5):1184–7. PubMed
Rider LG, Ruperto N, Pistorio A, Erman B, Bayat N, Lachenbruch PA, et al. Development of Adult Dermatomyositis and Polymyositis and Juvenile Dermatomyositis Response Criteria--Methodological Aspects: An American College of Rheumatology/European League Against Rheumatism/International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Rheumatology. 2016:2016. Submitted. PubMed
Rider LG, Aggarwal R, Bayat N, Erman B, Feldman BM, Huber AM, et al. A hybrid conjoint analysis model is proposed as the definition of minimal, moderate and major clinical improvement in juvenile dermatomyositis clinical trials. Arthritis Rheumatol. 2014;66(S11):S578.
Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, et al. A consensus hybrid definition using a conjoint analysis is the proposed response criteria for minimal and moderate improvement for adult polymyositis and dermatomyositis clinical trials. Arthritis Rheumatol. 2014;66(S11):S404.
Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol. 2015;67(10):2557–68. PubMed PMC
Utz KS, Hoog J, Wentrup A, Berg S, Lammer A, Jainsch B, et al. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. Ther Adv Neurol Disord. 2014;7(6):263–75. PubMed PMC
Amaya-Amaya M, Gerard K, Ryan M. Discrete choice experiments in a nutshell. In: Ryan M, Gerard K, Amaya-Amaya M, editors. Using Discrete Choice Experiments to Value Health and Health Care. Dordrecht: Springer; 2008.
de Bekker-Grob E, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012;21:145–72. PubMed
de Lautour H, Taylor WJ, Adebajo A, Alten R, Burgos-Vargas R, Chapman P, et al. Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds(R) Consensus Exercises. Arthritis Care Res (Hoboken) 2016;68(5):667–72. PubMed
Hansen P, Ombler F. A new method for scoring additive multi-attribute value models using pairwise rankings of alternatives. J Multi-Crit Decis Anal. 2008;15:87–107.
Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, et al. 2016 American College of Rheumatology (ACR) - European League Against Rheumatism (EULAR) Criteria for Minimal, Moderate and Major Clinical Response for Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2016;00(00):000. PubMed
Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314–24. PubMed PMC
Metz CE. Basic principles of ROC analysis. Semin Nucl Med. 1978;8(4):283–98. PubMed
Finney DJ. Statistical method in biological assay. 3. London: Charles Griffin; 1978.
Liengme BV. A Guide to Microsoft Excel 2002 for Scientists and Engineers. Butterworth-Heinemann; 2002.
Ruperto N, Meiorin S, Iusan SM, Ravelli A, Pistorio A, Martini A. Consensus procedures and their role in pediatric rheumatology. Curr Rheumatol Rep. 2008;10(2):142–6. PubMed
Delbecq A, Van de Ven A, Gustafson D. A guide to nominal group and delphi processes. Glenview, IL: Scott, Foresman and Company; 1975. Group techniques for program planning.
Ruperto N, Ozen S, Pistorio A, Dolezalova P, Brogan P, Cabral DA, et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. Ann Rheum Dis. 2010;69(5):790–7. PubMed
Piram M, Kone-Paut I, Lachmann HJ, Frenkel J, Ozen S, Kuemmerle-Deschner J, et al. Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis. 2014;73(12):2168–73. PubMed PMC
American College of Rheumatology Committee to Reevaluate Improvement Criteria. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum. 2007;57(2):193–202. PubMed
Streiner DL. Breaking up is hard to do: the heartbreak of dichotomizing continuous data. Can J Psychiatry. 2002;47(3):262–6. PubMed
Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727–35. PubMed
Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202–9. PubMed
Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658–66. PubMed
Volochayev R, Csako G, Wesley R, Rider LG, Miller FW. Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups. Open Rheumatol J. 2012;6:54–63. PubMed PMC